Dicot Pharma AB

As of June 30, 2026, Dicot Pharma AB carries a market capitalization of 693.74M, placing it among publicly traded companies globally. Its enterprise value stands at 445.34M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2026, Dicot Pharma AB has 3.47B shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Dicot Pharma AB maintains a current ratio of 30.69, meaning it holds 30.7x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

As of the close on October 22, 2026, Dicot Pharma AB's stock has declined approximately 73.86% over the past 52 weeks. The 50-day moving average sits at 0.23, while the 200-day moving average is 0.25.

These figures are as of June 30, 2026. Total book value stands at 255.30M, with working capital of 255.30M providing operational flexibility.

Dicot Pharma AB's most recent stock split took place on May 18, 2026.